Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy.
Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy.
复制标题
与紫杉醇和卡铂化疗相关的暴发性艰难梭菌结肠炎。
DOI：
10.1046/j.1525-1438.1999.99065.x
复制
发表时间：
1999
期刊：
影响因子：
--
通讯作者：
C. Lefèvre
中科院分区：
文献类型：
--
作者：
E. Resnik;C. Lefèvre
Resnik E，LeFevre CA.与紫杉醇和卡铂化疗相关的暴发性艰难梭菌结肠炎。伪膜性结肠炎通常与抗生素的使用有关。一些抗梭菌药物即使不使用相关的抗生素，也可能使患者易于发生艰难梭菌感染。感染通常是轻微的，然而，在极少数情况下，可能会遇到严重形式的伪膜性结肠炎。一名66岁女性IIIC期次优减容上皮性卵巢癌患者接受紫杉醇和卡铂治疗。病人患上了暴发性丙型肝炎。第二个化疗周期后三周出现艰难性结肠炎。入院前24小时开始出现严重症状;然而，尽管使用非处方药易蒙停和Pepto-Bismol进行自我治疗，但仍存在轻度恶心和腹泻一周。她最后一次使用抗生素是在7周前。患者立即住院接受积极治疗。尽管作出了所有努力，她的病情继续恶化，她去世了。严重C。艰难性结肠炎可能危及生命。接受化疗的患者如果出现严重腹泻，应进行C。很难在严重症状发作前及时诊断和干预可能会改善预后。
Resnik E, LeFevre CA. Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Pseudomembranous colitis is commonly associated with the use of antibiotics. Some antineoplastic agents even without associated antibiotic use can predispose patients to developing infection with Clostridium difficile. The infection is usually mild; however, in rare cases severe forms of pseudomembranous colitis may be encountered. A 66 year-old female with stage IIIC suboptimally debulked epithelial ovarian cancer was treated with paclitaxel and carboplatin. the patient developed fulminant C. difficile colitis three weeks after the second cycle of chemotherapy. Severe symptoms began 24 h prior to admission; however, mild nausea and diarrhea had been present for a week despite self-treatment with over-the-counter Imodium and Pepto-Bismol. Her last antibiotic use was seven weeks previously. The patient was hospitalized immediately for aggressive treatment. Notwithstanding all the efforts, her condition continued to deteriorate and she expired. Severe C. difficile colitis can be life threatening. Patients undergoing chemotherapy who develop significant diarrhea should be evaluated for C. difficile. Prompt diagnosis and intervention prior to onset of severe symptoms can potentially improve the outcome.